Quarterly ResultAug 11, 2026, 09:32 AM
Vor Bio's Telitacicept Phase 3 MG Trial On Track; Runway into 2029
AI Summary
Vor Bio reported its second quarter 2026 financial results and provided a corporate update. The company announced that enrollment for its telitacicept Phase 3 UPSTREAM MG trial is on track, with topline results expected in the first half of 2027, and enrollment is ongoing for the UPSTREAM SjD trial. Telitacicept also secured its fourth and fifth commercial approvals in China for Sjögren’s disease and IgA nephropathy. Vor Bio projects its $514.5 million pro-forma cash and investment balance will fund operations into early 2029.
Key Highlights
- Telitacicept Phase 3 UPSTREAM MG trial enrollment on track, with topline results anticipated in 1H 2027.
- Telitacicept received fourth and fifth commercial approvals in China for Sjögren’s disease and IgA nephropathy.
- Pro-forma cash and investment balance of $514.5 million is expected to provide a runway into early 2029.
- Cash, cash equivalents, and marketable securities were $466.1 million as of June 30, 2026.
- R&D expenses for Q2 2026 were $25.9 million, a decrease of $235.6 million from Q2 2025.
- G&A expenses for Q2 2026 were $21.9 million, an increase of $9.1 million from Q2 2025.
- Net loss for Q2 2026 was $62.8 million, a decrease of $1,510.9 million from Q2 2025.
- David Zaccardelli, Pharm.D., was appointed to the Board of Directors.
Price Impact
More from VOR